Document is current
Any future updates will be listed below
-
Authors
Avouac, Jérôme https://orcid.org/0000-0002-2463-218X
Ait-Oufella, Hafid https://orcid.org/0000-0002-2955-0183
Habauzit, Caroline
Benkhalifa, Salim
Combe, Bernard https://orcid.org/0000-0003-4002-1861
-
Funding
Funding for this research was provided by:
Celltrion Healthcare
- License Information
-
More Information
Article History
Received: 20 December 2024
Accepted: 13 February 2025
First Online: 28 February 2025
Declarations
:
: Jérôme Avouac has received honoraria from Galapagos, Lilly, Pfizer, Abbvie, Bristol-Myers Squibb, Sanofi, Roche-Chugai, Nordic Pharma, Medac, Novartis, Biogen, Fresenius Kabi, Janssen, Celltrion and MSD; and research grants from Bristol-Myers Squibb, Pfizer (Passerelle), Novartis (Dreamer), Fresenius Kabi, Galapagos and Nordic Pharma. Hafid Ait-Oufella is the co-founder of POLYGON Therapeutics, a biotech company that is developing therapeutic monoclonal antibodies to limit CV disease burden. Caroline Habauzit and Salim Benkhalifa are employees of Celltrion Healthcare. Bernard Combe has received honoraria from Abbvie, Celltrion, Chugaï, Lilly, Nordic and Pfizer.
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.
